June 6 (Reuters) - Seres Therapeutics ( MCRB ) said on

Thursday it has entered into a non-binding memorandum of

understanding with Nestlé Health Science for the sale of its

bacterial infection drug and related intellectual property

rights.

Under the terms of the pending agreement, Seres is due

to receive capital infusions, including an undisclosed upfront

payment.

The U.S. Food and Drug Administration last year

approved

the company's pill, Vowst, for treating adults with a type

of bacterial infection generally caused by he prolonged use of

antibiotics.

Seres entered into a deal with Nestle's health science

unit in 2021 to jointly commercialize the drug in the United

States.

The drugmaker expects to complete the transaction within the

next 90 days, subject to approval for certain customary

conditions.